The Alphabet-backed immunotherapy developer secured nearly $588m in what was reputedly the largest ever flotation for a preclinical life sciences company.
US-based stem cell medicine developer Sana Biotechnology raised almost $588m on Wednesday in an upsized initial public offering representing an exit for GV, a subsidiary of internet and technology group Alphabet. The company issued 23.5 million shares on the Nasdaq Global Select Market, up from a planned 15 million, priced at $25.00 each, above the…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.